Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants under 12 months, yet many infants born outside of the RSV season are unintentionally missed by hospital-based prevention programs. In this short video, experts will share practical, evidence-based strategies for identifying at-risk infants, communicating effectively with caregivers, and implementing catch-up protection using long-acting monoclonal antibody therapy.
This program has received an unrestricted educational grant or in-kind support from Sanofi Canada.